E&C Committee Plans Hearing On AI/ML, Including Data Privacy

The House Energy & Commerce Committee is the latest congressional panel to broach the burgeoning use of artificial intelligence/machine learning in health care, announcing plans for a hearing next Wednesday where experts will discuss what potential guardrails, such as a national privacy standard, are needed. E&C Chair Cathy McMorris Rodgers (R-WA) and health subcommittee Chair Brett Guthrie (R-KY) announced the hearing Tuesday (Nov. 21). So far, E&C lawmakers have heralded the bipartisan American Data Privacy and Protection Act as the...
Article Type: 
Inside Telehealth Daily News
Site Name: 
InsideHealthPolicy.com
Author: 
Cara Smith
Topics: 
Not Top Story

E&C Committee Plans Hearing On AI/ML, Including Data Privacy

The House Energy & Commerce Committee is the latest congressional panel to broach the burgeoning use of artificial intelligence/machine learning in health care, announcing plans for a hearing next Wednesday where experts will discuss what potential guardrails, such as a national privacy standard, are needed. E&C Chair Cathy McMorris Rodgers (R-WA) and health subcommittee Chair Brett Guthrie (R-KY) announced the hearing Tuesday (Nov. 21). So far, E&C lawmakers have heralded the bipartisan American Data Privacy and Protection Act as the...
Article Type: 
Daily News
Tags: 
AI
privacy
telehealth
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 11/24/2023
FDA Volume: 
Vol. 29, No. 47
CMS Issue: 
Inside CMS - 11/30/2023
CMS Volume: 
Vol. 26, No. 48
Author: 
Cara Smith
Topics: 
ISSUE: INSIDE CMS
ISSUE: FDA WEEK
AI
Congress

E&C Plans Oversight Hearing On ‘Biden’s Broadband Takeover’

A House Energy & Commerce panel will hold a hearing next Thursday (Nov. 30) where Republicans will raise strong concerns about the Federal Communication Commission’s regulatory oversight and spending on broadband. The move comes as the Biden administration seeks congressional support for an additional $6 billion to keep the Affordable Connectivity Program, a key broadband effort funded by the infrastructure law, going through December 2024 -- a request mired in politics and that an FCC official acknowledged is unlikely to...
Article Type: 
Inside Telehealth Daily News
Site Name: 
InsideHealthPolicy.com
Author: 
Cara Smith
Topics: 
Not Top Story

Senate Health Committee Dems Ask Drug Maker CEOs To Testify On High Prices

Senate health committee Democrats have asked chief executive officers of three pharmaceutical companies, Merck and Johnson & Johnson and Bristol Myers Squibb, to testify at a hearing in January on the high cost of prescription drugs. The hearing, scheduled for Jan. 25, 2024, is titled “Why Does the United States Pay, By Far, The Highest Prices In The World For Prescription Drugs?” The senators ask the CEOs of the three companies to clarify why the United States bears the distinction...
Article Type: 
Daily News
Tags: 
drug-patent
drug-reimbursement
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 11/24/2023
FDA Volume: 
Vol. 29, No. 47
CMS Issue: 
Inside CMS - 11/30/2023
CMS Volume: 
Vol. 26, No. 48
Author: 
Maaisha Osman
Topics: 
ISSUE: INSIDE CMS
ISSUE: FDA WEEK
HEALTH AUTO EMAIL
Congress
Rx Drugs

Budget Panel To CBO: Are You Updating Analysis Of IRA’s Impact As New Data Emerge?

The House Budget Committee wants to know whether the Congressional Budget Office (CBO) is continually updating its analysis of how the Inflation Reduction Act’s drug price controls will affect pharmaceutical innovation, noting new data have emerged since CBO initially estimated the law will lead to 13 fewer drugs coming to market over the next 30 years. Committee Chair Jodey Arrington (R-TX), the committee’s Health Care Task Force Chair Michael Burgess (R-TX) and other members of the GOP-led health task force...
Article Type: 
Inside Drug Pricing Daily News
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 11/27/2023
IDP Volume: 
Vol. 6, No. 48
Author: 
Gabrielle Wanneh

Budget Panel To CBO: Are You Updating Analysis Of IRA’s Impact As New Data Emerge?

The House Budget Committee wants to know whether the Congressional Budget Office (CBO) is continually updating its analysis of how the Inflation Reduction Act’s drug price controls will affect pharmaceutical innovation, noting new data have emerged since CBO initially estimated the law will lead to 13 fewer drugs coming to market over the next 30 years. Committee Chair Jodey Arrington (R-TX), the committee’s Health Care Task Force Chair Michael Burgess (R-TX) and other members of the GOP-led health task force...
Article Type: 
Daily News
Tags: 
drug-negotiation
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 11/30/2023
CMS Volume: 
Vol. 26, No. 48
Author: 
Gabrielle Wanneh
Topics: 
ISSUE: INSIDE CMS
Congress
Medicare
Rx Drugs

FTC Files Amicus Brief In Insulin Case, Punctuating Intent To Police Orange Book Listings

The Federal Trade Commission (FTC) filed an amicus brief in an ongoing case over alleged improper listing in FDA’s “Orange Book” of drug patents, underscoring its intent to take a lead role in scrutinizing patent listings and its view that patents related to device components of combination products don’t belong in the Orange Book, an issue on which FDA has never offered clear guidance to drug companies. FTC announced the filing in the case Mylan Pharmaceuticals Inc., et al. v....
Article Type: 
Daily News
Tags: 
drug-patent
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 11/24/2023
FDA Volume: 
Vol. 29, No. 47
Author: 
Jessica Karins
Topics: 
ISSUE: FDA WEEK
Rx Drugs
The Courts

FTC Simplifies Subpoena Process To Protect Consumers Using AI Products, Services

The Federal Trade Commission Tuesday (Nov. 21) voted to approve an omnibus resolution that will aid the agency in potential investigations of AI-related products and services. The resolution alters FTC’s civil investigative demand issuing process by allowing one commissioner to issue the subpoena rather than requiring a vote by all the commissioners. A civil investigative demand (CID) by the Federal Trade Commission is the first step in the process of the agency pursuing an investigation into a company. The business...
Article Type: 
Daily News
Tags: 
AI
telehealth
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 11/24/2023
FDA Volume: 
Vol. 29, No. 47
CMS Issue: 
Inside CMS - 11/30/2023
CMS Volume: 
Vol. 26, No. 48
Author: 
Emma Beavins
Topics: 
ISSUE: INSIDE CMS
ISSUE: FDA WEEK
AI

BIO: Orange Book Issues Should Be Resolved With FDA Guidance, Not FTC Enforcement

The biotechnology organization is asking the Federal Trade Commission (FTC) to step back from taking enforcement action over patents it believes are improperly listed in FDA’s “Orange Book” and for FDA to instead issue more guidance on the matter, although FDA has signaled it is uninterested in acting as an enforcer on patent matters and is willing to allow FTC the lead role. The Biotechnology Innovation Organization (BIO), the trade group for biotech companies, published a post Tuesday (Nov. 21)...
Article Type: 
Daily News
Tags: 
drug-patent
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 11/24/2023
FDA Volume: 
Vol. 29, No. 47
Author: 
Jessica Karins
Topics: 
ISSUE: FDA WEEK
Medical Devices
Rx Drugs

Behavioral Health Reforms Line Up For Next Legislative Package

Lawmakers have teed up several behavioral health reforms to slip into the next major legislative package this year or in early 2024, including proposals to integrate mental health with primary care and reauthorize the SUPPORT Act -- all while the Biden administration has approved more state plans to fund mental health crisis response teams and is trying to reduce substance use disorder stigma in the workforce. Advocates were saddened Sept. 30 when Congress let the 2018 law that created several...
Article Type: 
Daily News
Tags: 
mental-health
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 11/30/2023
CMS Volume: 
Vol. 26, No. 48
Author: 
Dorothy Mills-Gregg
Topics: 
ISSUE: INSIDE CMS
HEALTH AUTO EMAIL
Biden Health Agenda
Congress
Medicaid
Medicare

Pages

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.